ArticleCancer medicine2016

New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.

Katia Cannita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.